5632-13-3

Basic information

• Product Name: 4-Aminomethylquinoline hydrochloride
• Synonyms: C-QUINOLIN-4-YL-METHYLAMINE;C-QUINOLIN-4-YL-METHYLAMINE HYDROCHLORIDE;CHEMBRDG-BB 4002122;4-AMINOMETHYL QUINOLINE HYDROCHLORIDE;QUINOLIN-4-YLMETHYL-AMINE;Quinolin-4-ylmethyl-amide;2-BENZOTHIOAZOLEACETONITRILE;Quinolin-4-ylmethanamine hydrochloride
• CAS NO: 5632-13-3
• Molecular Formula: C₁₀H₁₀N₂
• Molecular Weight: 194.66
• Mol File: 5632-13-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 319.958 °C at 760 mmHg
• Flash Point: 173.268 °C
• Appearance: /
• Density: 1.157 g/cm³
• Vapor Pressure: 3.39E-05mmHg at 25°C
• Storage Temp.: 2-8°C(protect from light)
• PKA: 7.81±0.29(Predicted)
• CAS DataBase Reference: 4-Aminomethylquinoline hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Aminomethylquinoline hydrochloride(5632-13-3)
• EPA Substance Registry System: 4-Aminomethylquinoline hydrochloride(5632-13-3)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 5632-13-3(Hazardous Substances Data)

Usage

Uses

4-Aminomethylquinoline Hydrochloride is used to prepare 2,4-Diaminoquinazolines and analogs to study their use as treatment for mycobacterial infections.

InChI:InChI=1/C10H10N2.ClH/c11-7-8-5-6-12-10-4-2-1-3-9(8)10;/h1-6H,7,11H2;1H

Upstream product

• 2973-27-5 quinoline-4-carbonitrile 
• 126921-64-0 (E)-quinoline-4-carbaldehyde Oxime 
• 7647-01-0 hydrogenchloride 
• 64-19-7 acetic acid 
• 3964-04-3 4-bromoquinoline 
• 1001242-54-1 2-(quinolin-4-ylmethyl)-1H-isoindole-1,3(2H)-dione 
• 4363-93-3 quinoline-4-carboxaldehyde 
• 39977-74-7 4-quinolinecarboxaldehyde oxime 

Downstream Products

• 858277-78-8 N-acetyl-sulfanilic acid-([4]quinolylmethyl-amide) 
• 78811-99-1 4-Guanidinomethylquinoline hydrochloride 
• 76518-57-5 isoquinolin-5-ylmethanol 
• 1202040-91-2 5-bromo-2-(quinolin-4-ylmethyl)aminosulfonyl-benzoic acid methyl ester 
• 1173997-56-2 C₁₇H₁₅N₃S 
• 1384118-27-7 5-chloro-3-((3,5-dimethylphenyl)sulfonyl)-N-(quinolin-4-ylmethyl)-1H-indole-2-carboxamide 
• 1416568-10-9 4-(3-chloro-2-cyanophenoxy)-N-(4-quinolinylmethyl)benzenesulfonamide 
• 1416568-13-2 4-(phenylmethyl)-N-(4-quinolinylmethyl)benzenesulfonamide 
• 1416568-23-4 4-(2-chloro-4-cyanophenoxy)-N-(quinolinylmethyl)-benzenesulfonamide 
• 1416568-24-5 methyl 2-[4-[[(4-quinolinylmethyl)amino]sulfonyl]phenoxy]-benzoate 
• 1438474-98-6 4-[2-(2-pyridinyl)ethynyl]-N-(4-quinolinylmethyl)-benzenesulfonamide 
• 1544696-08-3 C₂₆H₃₆N₂O₃Si 

Relevant articles and documents

A quinoline alkaloid rich Quisqualis indica floral extract enhances the bioactivity

A volatile alkaloid quinoline-4-carbonitrile (QCN) was isolated from the floral extract of Quisqualis indica. Major compounds were trans-linalool oxide (1.0, 4.5%), methyl benzoate (1.0, 4.0%), 2,2,6-trimethyl-6-vinyl-tetrahydropyran-3-one (7.4, 17.8%), 2,2,6-trimethyl-6-vinyl-tetrahydropyran-3-ol (1.0, 1.2%), (E,E)-α-farnesene (29.1, 16.1%), QCN (5.7, 1.3%) in live and picked flowers, respectively. Flower compositions were altered due to change in enzymatic reaction at the time of picking. Some rearrangements of oxygenated terpenoids occurred in the process of hydrodistillation to obtain essential oil. Chemical synthesis of QCN and its selectively reduced products derived from QCN were prepared through green reaction process. The catalytic modification of QCN has produced quinoline-4-methylamine; the later compound has shown enhanced bio-activities. QCN and floral extract (absolute) have shown potential anti-inflammatory and antioxidant activities. Besides, floral absolute has shown significant anti-inflammatory and antioxidant activities due to improved QCN (19.7%) content to synergize amongst terpenoids and benzenoids as compared to the essential oil with 1.1% of QCN.

Discovery and Optimization of 1-(4-chloro-3-(trifluoromethyl)-phenyl)-3-(2-(amino)pyridin-3-yl)ureas as Novel KDR Kinase Inhibitors

Kinase insert Domain-containing Receptor (KDR) is one of the currently validated targets for anticancer drug discovery and development. Herein, a series of o-amino-arylurea derivatives have been synthesized and evaluated for their kinase inhibitory activity. The optimization on the basis of biological screening and molecular modeling resulted in obvious increase in KDR kinase inhibitory activity compared with the hit compound. Eventually, we identified a potent inhibitor 5a of 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-((quinolin-4-ylmethyl) amino)pyridin-3-yl)urea scaffold against KDR (IC50 = 0.0689 μM), which can serve as good starting point for further KDR inhibitor optimization and development.

N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS

Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein (1), Q, A, R1, R2, R3 and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula (1) and methods for treating helminth infections comprising administration to an animal a parasiticidally effective amount of a compound or a composition of the invention.